Gene mutations detected in blood may predict risk of one of the most common forms of adult leukemia a decade before patients are diagnosed with the disease, according to a new study by Weill Cornell Medicine and NewYork-Presbyterian investigators.
The complex life cycle of the parasite that causes malaria has made it a difficult foe to beat. But new insights on how the parasite is transmitted from humans to the mosquitoes that spread malaria may lead to new ways to control this deadly disease.
Dr. Olivier Elemento, a renowned computational biologist and leader in the field of computational genomics and biomedicine, has been named director of the Caryl and Israel Englander Institute for Precision Medicine at Weill Cornell Medicine.
Weill Cornell Medicine has been awarded a five-year, $11.3 million Specialized Programs of Research Excellence grant from the National Cancer Institute to improve the detection, diagnosis and treatment of prostate cancer.
Combining genetic information from a patient’s tumor cells with three-dimensional cell cultures grown from these tumors and rapidly screening approved drugs can identify the best treatment approaches in patients for whom multiple therapies have failed.
A powerful next-generation genome-sequencing test developed at Weill Cornell Medicine can detect mutations that guide precision cancer treatment with over 95 percent accuracy.
Researchers from Weill Cornell Medicine, Columbia University Medical Center, NewYork-Presbyterian and NYC Health + Hospitals/Harlem seek to extend the success of precision medicine in cancer to a broad range of diseases.
The steroid dexamethasone could potentially deter the growth of a prostate cancer subtype that was previously thought to be difficult to treat with medications.
A new collaboration involving Weill Cornell Medicine will equip researchers with more precise and reliable genomic data when investigating instances of cancer.
